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Abstract  
Rett syndrome (RTT) is an X-linked neurological disorder caused by 
mutations in the MECP2 gene. The majority of RTT missense mutations 
disrupt the interaction of MeCP2 with DNA or the NCoR/SMRT co-repressor 
complex. Here we show that the “NCoR/SMRT Interaction Domain” (NID) of 
MeCP2 directly contacts TBL1 and TBLR1, two paralogues that are core 
components of NCoR/SMRT. We determine the co-crystal structure of the 
MeCP2 NID in complex with the WD40 domain of TBLR1 and confirm by in 
vitro and ex vivo assays that mutation of interacting residues of TBLR1 and 
TBL1 disrupts binding to MeCP2. Strikingly, the four MeCP2 NID residues 
mutated in RTT are those that make most extensive contacts with TBLR1. 
Moreover, missense mutations in the gene for TBLR1 that are associated with 
intellectual disability also prevent MeCP2 binding. Our study therefore reveals 
the molecular basis of an interaction that is crucial for optimal brain function. 
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Significance statement 
 
The	  nuclear	  protein	  MeCP2	  links	  epigenetics,	  brain	  function	  and	  
neurodevelopmental	  disease.	  Mutations	  in	  the	  MECP2	  gene	  cause	  Rett	  syndrome,	  
making	  it	  imperative	  to	  determine	  its	  mechanism	  of	  action.	  One	  protein	  domain	  
targets	  MeCP2	  to	  methylated	  DNA,	  but	  little	  was	  known	  about	  a	  second	  essential	  
domain	  except	  that	  it	  interacts	  with	  a	  gene	  silencing	  complex.	  We	  determined	  that	  
TBL	  subunits	  of	  NCoR/SMRT	  bind	  MeCP2	  and	  solved	  the	  structure	  of	  the	  binary	  
complex.	  Strikingly,	  amino	  acids	  mutated	  in	  Rett	  syndrome	  are	  precisely	  those	  that	  
intimately	  contact	  the	  TBL	  subunits.	  Furthermore,	  mutations	  in	  TBL	  proteins	  that	  
cause	  intellectual	  disability	  prevent	  the	  interaction	  with	  MeCP2.	  This	  suggests	  that	  
the	  TBL-­‐MeCP2	  interaction	  is	  essential	  for	  brain	  function	  and	  may	  be	  accessible	  to	  
therapeutic	  modulation.	  
 
Introduction 
The methyl-CpG binding protein MeCP2 is a chromatin-associated factor that 
is highly expressed in the brain (1, 2). Loss-of-function mutations in MeCP2 
lead to the severe pediatric neurological disorder, Rett syndrome (RTT) (3), 
which affects around 1 in 10,000 girls. In addition, extra copies of the gene 
cause MeCP2 duplication syndrome (4, 5), a distinct intellectual disability 
disorder that predominantly affects males (6). The importance of MeCP2 for 
brain function has prompted investigation of its molecular function. The 
protein was identified because of its ability to bind DNA via its methyl-CpG 
binding domain (MBD) (1, 7) and many residues mutated in RTT disrupt this 
interaction (8-11). In addition to DNA, numerous protein partners of MeCP2 
have been reported (11). Of these, only the interactions with the nuclear 
receptor co-repressor complexes NCoR and its close relative SMRT (silencing 
mediator of retinoic acid and thyroid receptors) (NCoR/SMRT) (12-14) are 
known to be disrupted by RTT missense mutations (13). Accordingly, Rett 
missense mutations outside the MBD are found clustered within the so-called 
NCoR/SMRT Interaction Domain (NID, Fig. 1a, S1a) (13). One NID mutation, 
R306C, causes a severe RTT-like phenotype in mice (13, 15, 16). Moreover, 
mouse models of MeCP2 duplication syndrome suggest that both the MBD 
and the NID must be intact for this adverse molecular pathology to develop 
(16, 17).	  	  
These findings indicate that the NID mediates an essential function of MeCP2. 
This function may be recruitment of the NCoR/SMRT co-repressor complexes 
to chromatin. Alternatively, the NID may perform other essential roles, such as 
DNA binding, whose loss leads to RTT(16). In an attempt to distinguish these 
possibilities we investigated the molecular basis of the interaction between 
MeCP2 and NCoR/SMRT. The latter are ~1.2 MDa multi-subunit complexes 
that include NCoR1 (and/or SMRT), HDAC3, GPS2 and TBL1 (and/or its 
paralogue TBLR1) (18-21). We show here that the TBL1 and TBLR1 subunits 
(89% identical in amino acid sequence in humans; Fig. S1b) are direct 
MeCP2 binding partners. The crystal structure of a minimal MeCP2-TBLR1 
complex at 2.5 Å resolution reveals that the four MeCP2 NID residues most 
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intimately contacting TBLR1 are the same residues that are mutated in RTT. 
This finding strongly suggests that sustaining this interaction is the primary 
function of the NID. Mutations in the TBLR1 WD40 domain that disrupt 
MeCP2 NID binding in vitro also prevent recruitment of TBL1 to 
heterochromatic foci in cells. Finally, we show that intellectual disability-
associated missense mutations in TBLR1 disrupt its interaction with MeCP2, 
supporting the view that this interaction is critical for brain function.  
Results 
MeCP2 interacts with NCoR/SMRT and TBL1 in cells 
Previously, we showed that an MeCP2-derived NID peptide could pull-down 
an NCoR1 fragment spanning residues 197 to 598 (13). To define the MeCP2 
binding site on the NCoR/SMRT complex, we used a similar strategy with 
FLAG-tagged NCoR1 fragments expressed in HeLa cells (Fig. 1a,b). Like 
NCoR1(197-598), NCoR1 fragments spanning residues 197-490 and 227-490 
were bound efficiently by a wild-type NID peptide corresponding to residues 
285-313 (MeCP2-NID, Fig. 1a,b). Two further N-terminal truncations showed 
reduced binding (residues 241-490) or failed to bind (297-490) (Fig. 1b). None 
of these constructs bound to a control NID peptide containing the RTT 
mutation K305R, confirming specificity. We noted that residues 227-297 of 
NCoR1, which appear to be involved in binding MeCP2, overlap with the 
NCoR1 region that interacts with TBL1 and TBLR1 (NCoR1 residues 247-
256) (22). This suggested that the MeCP2-NCoR1 interaction might be 
indirect, mediated by interaction of MeCP2 with endogenous TBL1/TBLR1 
present in cell lysates. We used a co-immunoprecipitation (co-IP) assay to 
test whether the ability of FLAG-tagged NCoR1 deletion fragments to bind to 
endogenous TBLR1 matched their ability to bind MeCP2. Indeed the 
NCoR1(241-490) and (297-490) fragments showed reduced and absent 
binding to TBLR1, respectively (Fig. 1c). The correlation between pull-down 
efficiency of NCoR1 fragments by the NID peptide and TBLR1 suggests that 
the MeCP2-NCoR1 interaction is bridged by TBL1/TBLR1. 
MeCP2 binds directly to TBL1 and TBLR1 
TBLR1 and TBL1 have an N-terminal tetramerisation domain, which interacts 
with NCoR1, linked to a C-terminal WD40 domain (Figs. 1a,2a) (27). To 
determine the minimal fragment of TBL1 that binds MeCP2, we expressed 
FLAG-tagged full-length, N-terminal and C-terminal fragments of TBL1 in 
HeLa cells (Fig. 2a,b). Full-length TBL1 and a C-terminal fragment of TBL1 
(residues 176-527) were efficiently precipitated by the MeCP2 NID peptide, 
whereas the N-terminal domain of TBL1 (residues 1-181) was not (Fig. 2b). 
None of the deletion mutants bound to a peptide carrying the K305R RTT 
mutation. Furthermore, shortening of the WD40 domain to disrupt the first or 
last repeat (FLAG-TBL1 (200-527) or FLAG-TBL1 (176-488)) disrupted the 
interaction with NID peptide (Fig 2b). These deletions likely destabilize the 
WD40 domain, indicating that an intact TBL1 WD40 domain is required to 
bind MeCP2.  
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We next asked whether the NID peptide could interact directly with purified 
recombinant mouse TBL1 and TBLR1 C-terminal WD40 domains (CTDs Fig. 
2c, Fig. S2a). TBL1 WD40 domain was efficiently pulled down by wild-type 
NID but not by RTT mutant peptides or a peptide containing phosphoThr308, 
a modification known to interfere with NID binding (Fig. 2c)(23). An MeCP2 
peptide up to and including residue 308, corresponding to a hypomorphic 
mutation (24) with reduced NCoR binding (13), also showed weakened 
binding to TBL1 (Fig. 2c). These results confirm that MeCP2 NID can bind 
directly to the WD40 domain of TBL1, both in cell extracts and in vitro. Using 
surface plasmon resonance (SPR) we measured binding constants (KD) for 
alternative NID peptides (NIDs, residues 285-309; or NID residues 285-313) 
with the mouse TBLR1 carboxy-terminal domain (TBLR1-CTD; residues 134-
514) (Fig. 2d, Fig. S2b). Wild-type TBLR1-CTD bound MeCP2-NID and 
MeCP2-NIDS with apparent KDs of 9.5 ± 0.5 µM and 12.9 ± 0.8 µM, 
respectively. Similar binding constants suggest that MeCP2 residues up to 
and including 309 are sufficient for binding. Finally, we find that a minimal 11-
mer peptide, spanning residues 298 to 309 of MeCP2, is sufficient to bind 
TBLR1 in fluorescence anisotropy assays (Fig. S2c). While the binding affinity 
of the binary interaction is relatively low, binding in vivo might be enhanced by 
the tetrameric structure of TBL1/TBLR1. 
 
 TBL1 chimeras show differential binding to MeCP2  
As progressive deletions that truncate the WD40 β-propeller domain 
destabilise the fold, we devised a “phylogenetic” strategy to identify residues 
required for MeCP2 binding. MeCP2 is only found in vertebrates, but TBL1 
homologues are present throughout metazoans. By identifying evolutionarily 
remote TBL1 homologues, we were able to construct chimaeric TBL1 proteins 
that do not bind MeCP2, while retaining integrity of the WD40 domain. A 
Drosophila orthologue, Ebi (83% identity to human and mouse) was 
successfully pulled down by MeCP2 NID peptide, but a sponge ortholologue 
(Amphimedon queenslandica: 58% identity with human and mouse) was not 
recovered (Fig S3a). To map differences between mouse and sponge 
sequences, approximate quarters of the mouse TBL1 WD40 sequence were 
replaced with equivalent segments from sponge (Fig. 3a). Replacing the 
second quarter of the mouse sequence (TBL1-chimera1) or the first and last 
quarters (TBL1-chimera3) showed wild-type binding to MeCP2 peptide, while 
replacement of the third quarter (TBL1-chimera2) abolished binding (Fig. 3a). 
To refine the map, we generated a series of mouse TBL1 mutants where up 
to four consecutive residues were altered to equivalent residues in the sponge 
third quarter sequence (Fig. S3b,c). Only mutants with substituted 362-364 
and 405-406 lost binding (Fig. S3c). Further mapping identified E364G as a 
single missense mutation in TBL1 that abolishes the MeCP2 interaction (Fig. 
3b), but importantly did not prevent incorporation of TBL1 into the 
NCoR/SMRT complex (Fig. S3d). This residue maps to a surface of human 
TBLR1 (hTBLR1) that is associated with peptide ligand binding in related 
proteins (Fig. S3e) (25, 26).  
MeCP2 NID binds the top surface of TBLR1 WD40 domain 
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To fully define the intermolecular interaction we determined a co-crystal 
structure of mouse TBLR1 C-terminal domain (TBLR1-CTD) with MeCP2 
NIDS peptide. Crystals diffracted to 2.5 Å in space group P1. The structure 
was solved by molecular replacement using the coordinates of hTBLR1 as a 
search model (99.5% identity, PDB ID 4LG9, (26)). Four molecules of TBLR1-
CTD are present in the asymmetric unit. After initial refinement, Fo-Fc maps 
showed clear electron density in two copies of TBLR1-CTD into which the 
NIDS peptide was built. The final model showed good stereochemistry (Table 
S1) (27). Chain A is the best-defined copy of TBLR1-CTD, where residues 
155-513 were visible with the exception of short loops at residues 203-204 
and 217-223. Chains C and D lacked peptide and displayed poor electron 
density. While the backbone of these chains could be discerned, many loops 
and side chains could not be modelled. We therefore restrict our discussion to 
TBLR1 chain A. Only residues 296 to 307 of the NIDS peptide could be 
modelled with confidence (Fig. S4a).  
The TBLR1 WD40 domain is an eight-bladed β-propeller domain with a 
central channel (Fig. 4a,b) (26). As in other WD40 domains, the C-terminal β-
propeller contains a β-strand from the first WD40 repeat sequence (Fig. 4a) 
(28). The NIDS peptide binds the top face of the central channel, a common 
interaction interface (25, 28). At the deepest point the peptide is 
approximately 10 Å inside the channel (Fig. 4b), burying a surface area of 532 
Å2 on TBLR1 (Fig. 4c). The TBLR1 interaction surface is highly 
electronegative (Fig. 4d), enabling recognition of the cluster of basic residues 
in the NID. Surface conservation calculations using vertebrate TBLR1 
sequences show that the top face is conserved, consistent with a role in 
protein-protein interactions (Fig. 4e) (29).  
Four key residues of MeCP2 interact with TBLR1 
Side chains of residues 301-306 of MeCP2 were well resolved suggesting that 
this region forms the core of the interaction (Fig. 5a,b). The most striking 
feature of the NID is a tight backbone turn stabilised by R306MeCP2 via a 
network of intra- and inter-molecular interactions within the complex. This 
residue forms a salt bridge with E171TBLR1 and close contacts with the 
backbone carbonyl groups of T299MeCP2 and L301MeCP2 (Fig. 5a). These 
interactions and stereochemical constraints imposed by P302MeCP2 enable the 
peptide to enter the central channel (Fig. 5a). P302MeCP2 is part of a stretch of 
hydrophobic residues in the N-terminal part the MeCP2 core interacting 
region, which also includes V300MeCP2, L301MeCP2 and I303MeCP2. P302MeCP2 is 
buried in a hydrophobic pocket created by three aromatic side chains: 
Y395TBLR1, F420TBLR1 and Y446TBLR1 (Fig. 5b). The hydroxyl group of 
Y446TBLR1 provides a peptide backbone contact, forming a hydrogen bond 
with the main chain carbonyl of V300MeCP2 (Fig. 5b).  
In addition to R306MeCP2, the C-terminal portion of the core NID has two 
further basic residues: K304MeCP2 and K305MeCP2. Both residues have 
extensive hydrogen bonding and ionic interactions with TBLR1. K304MeCP2 
and K305MeCP2 form hydrogen bonds with main chain and side chain moieties 
of N353TBLR1, respectively (Fig. 5b). K305MeCP2 is further stabilised by 
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hydrogen bonding with D369TBLR1 and an ionic interaction with E351TBLR1, 
which lies 3.1 Å away (Fig. 5b). Notably, E351TBLR1 is equivalent to E364 in 
TBL1, which proved to be essential for the interaction with MeCP2 based on 
our earlier phylogenetic mapping (Fig. 3b, S3e). This mode of recognition 
differs from other WD40 domain peptide interactions involving basic motifs, 
such as recognition of modified arginine and lysine residues in histone tails, 
where aromatic cages stabilize the positive charges (Fig. S4b) (30, 31).  
RTT mutations disrupt individual MeCP2-TBLR1 contacts 
Of the 25 MeCP2 NIDS peptide residues present in the co-crystal structure 
(Fig. 1a), only four make extensive interactions with TBLR1. Strikingly, 
missense substitutions at each of these four residues (P302, K304, K305 and 
R306) are reported in multiple independent cases of RTT. On the other hand, 
pathological substitutions at other NID residues are not reported in a database 
with over 1000 RTT mutations (32). The new structure explains in molecular 
detail why known RTT mutations in the NID likely prevent association with the 
NCoR/SMRT co-repressor complex.  
The most common RTT mutation in this region, R306CMeCP2, disrupts TBLR1 
binding in two ways. Firstly, loss of the arginine side chain would prevent the 
formation of a salt bridge with E171TBLR1 (Fig. 5c). Secondly, the mutant 
cysteine side chain is short and lacks the hydrogen bonding capacity of the 
arginine guanidinium group, and so would be unable to stabilize the peptide 
conformation (Fig. 5c). RTT mutation K304EMeCP2 is a charge reversal 
mutation that likely prevents binding of the peptide by electrostatic repulsion 
(Fig. 5d). Two further RTT mutations, P302RMeCP2 and K305RMeCP2 introduce 
larger side chains than those present in the wild-type sequence. The arginine 
side chain of P302RMeCP2 could not be accommodated in the hydrophobic 
pocket where P302MeCP2 binds and would likely also disrupt the kinked 
backbone conformation of the peptide (Fig. 5e). K305RMeCP2 is superficially a 
conservative substitution. Given the precise arrangement of the MeCP2-NIDS 
peptide in the TBLR1 central channel, however, the longer arginine side chain 
creates a steric clash that would not be accommodated (Fig. 5f).  
TBLR1 mutants disrupt interactions with MeCP2 
To assess the importance of the TBLR1 residues that contact MeCP2, we 
tested a series of TBLR1 site-directed mutants using the SPR assay (Fig. 6a). 
E171ATBLR1 and E171QTBLR1 assessed the importance of ionic interactions 
and hydrogen bonds with R306MeCP2 and showed a greater than four-fold 
reduction in binding to MeCP2 (Fig. 6b). These results suggest that the salt 
bridge with R306MeCP2 is more important than hydrogen bonding. Similarly, 
E351ATBLR1 showed weaker binding, whereas E351DTBLR1 retained wild-type 
affinity for MeCP2 (KD = 11.4 ± 0.5 µM), indicating the importance of ionic 
interactions with K305MeCP2 (Table 1). D369ATBLR1, which is also expected to 
prevent binding to K305MeCP2, and D313NTBLR1, which should affect the 
electronegative binding surface, both abolished binding to NID peptide (Table 
1, Fig. 6b,S5a). Finally, Y446FTBLR1 mutation tested the importance of the 
main chain interactions with V300MeCP2. The Y446FTBLR1 mutant showed close 
to wild-type binding, indicating a minor contribution to the interaction. As a 
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control C214TBLR1, a residue distant from the MeCP2 binding site, was 
mutated to serine, and this mutant bound similarly to wild-type TBLR1. Only 
small variations in melting temperature of the mutant proteins were observed 
(deviations of ± 3ºC from wild-type Tm, 62ºC) in thermal denaturation assays 
(Fig. S5b), indicating that structural integrity of the proteins is unaffected. 
These results corroborate the structural data, as implicated residues are 
indeed required for efficient TBLR1 binding to MeCP2. 
TBL1 mutants fail to co-localise with MeCP2 
The structural analysis used only the TBLR1-CTD and a NID peptide. To 
validate these findings in living cells with full-length proteins, we tested for 
recruitment of TBL1/TBLR1 mutants to heterochromatin by MeCP2. We 
previously demonstrated that whereas TBL1-mCherry alone accumulates in 
the cytoplasm of NIH-3T3 cells, it is targeted to densely methylated 
heterochromatin when co-expressed with EGFP-MeCP2 (13). The interaction 
is dependent on the presence of a functional NID and is disrupted by the 
missense RTT mutation R306CMeCP2 (13). As TBLR1-mCherry constructs 
gave a weak fluorescent signal compared with TBL1-mCherry, we introduced 
the equivalent mutations into TBL1 (Fig. 6a). Unlike wild-type TBL1-mCherry, 
TBL1 point mutants E184A, D326N, E364A and D382A showed little or no co-
localisation with MeCP2 at heterochromatic foci (Fig. 6c). Mutations for which 
corresponding mutations in TBL1 do not affect TBLR1 binding in vitro, such as 
Y459F, showed a wild-type co-localisation (Fig. 6c). The correlation between 
the effect of mutations on protein distribution ex vivo and the effect on binding 
in vitro suggests that the molecular recognition observed with minimal 
interacting domains recapitulates the behaviour of full-length proteins in cells. 
Furthermore, all TBL1 mutants were able to co-IP HDAC3 when transfected 
into cells, further supporting the conclusion that these mutants retain a native 
fold (Fig. S5c). 
Disease-associated TBLR1 mutations block MeCP2 binding 
If a direct interaction between the MeCP2 and TBLR1 is critical for MeCP2 
function, we expected that mutations in TBLR1 or TBL1 might also give rise to 
neurological disease. The database of genomic variation and phenotype in 
humans using Ensembl resources (DECIPHER (33)) revealed six missense 
mutations in TBL1XR1, the gene encoding TBLR1: H441R, H213Q, A311P, 
D369E, D370Y and P444R associated with intellectual disability and 
developmental delay. An additional missense mutation in TBL1XR1, L282P, 
was reported to be associated with sporadic autism spectrum disorder (34). 
All of these mutations map to the WD40 domain of TBLR1 (Fig. 7a, S6a). Five 
mutations (H213Q, D370Y, H441R, A311P and L282P) are likely to disturb 
the entire fold as they map either to the WD40 consensus sequence (25, 28) 
or the hydrophobic core of the protein (35).  
Two mutations, P444R and D369E, were of more interest, as they map close 
to the MeCP2 binding site. Introduction of a large positively charged residue 
at P444 might destabilise the hydrophobic binding site formed by Y395, F420 
and Y446 and thus interfere with MeCP2 binding (Fig. S6a), while the 
apparently conservative D369E mutation might block interaction with 
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K305MeCP2 (Fig. S6a). To test whether these two mutations prevent interaction 
with MeCP2, we co-precipitated wild-type or mutant FLAG-TBL1-CTD with 
MeCP2 NID peptide. We included E184A as a non-binding control. Neither 
D382ETBL1 (D369ETBLR1) nor P457RTBL1 (P444RTBLR1) is efficiently pulled down 
by MeCP2 NID peptide (Fig. 7b). Furthermore, these two mutants are not 
recruited to heterochromatic foci by MeCP2 in cells (Fig. 7c). Both of these 
mutants are incorporated efficiently into NCoR/SMRT complexes (Fig. S6b) 
and show only small effects on thermal stability (Fig. S6c), indicating that the 
mutations did not affect the overall structure of the protein. Consistent with the 
pull-down assay, the D369E mutation substantially reduced binding to the NID 
peptide while P444R had a milder effect (Fig. S6d). These clinically important 
mutations in TBL1/TBLR1 therefore interfere with binding to MeCP2 in cells. 
Discussion 
The clustering of RTT mutations indicates that there are two functionally 
important regions in MeCP2. While the role of the methylated DNA binding 
domain is well established, the effect of mutations that cluster in the NID was 
uncharacterised at the molecular level. Previous studies showed that the 
MeCP2 NID is required for interactions with the NCoR/SMRT complex in cells. 
Here we show that the NCoR/SMRT complex subunit TBL1, and its paralogue 
TBLR1, bind MeCP2 directly via a WD40 domain (Fig. 2). To our knowledge, 
this location is unique among known NCoR/SMRT recruiters, which 
consistently interact with the NCoR/SMRT scaffold proteins themselves.  
The most striking aspect of the co-crystal structure is that all residues in the 
MeCP2 NID that are mutated in RTT play a direct role in binding TBLR1. The 
exact coincidence between the four residues crucial to the MeCP2–
TBL1/TBLR1 interaction and four residues mutated in RTT makes it highly 
likely that TBL1 and TBLR1 are essential partners of MeCP2. It is notable that 
over 200 independent cases of the R306C mutation are reported, whereas 
mutation of P302 to R, L or A has been seen 23 times (32). Missense 
mutations at K305 and K304 are rarer, having been reported only 4 and 2 
times respectively. Importantly, mutations at each of these amino acids are 
almost certainly causal due to their demonstrated absence in both parents of 
at least one patient (13, 32).  
Given the importance of the MeCP2-TBL1/TBLR1 interaction, it might be 
expected that mutations in TBL1 or TBLR1 would lead to RTT. TBLR1 
missense mutations have been reported in cases of developmental delay and 
sporadic autism spectrum disorder (33, 34), but so far not in patients 
diagnosed with RTT. Intriguingly, at least two of these mutations disrupt the 
interaction with MeCP2 in pull-down assays and in cells (Fig. 7). Differences 
in clinical presentation between MECP2 and TBL mutations might be 
expected, as the MECP2 gene is X-linked and therefore X chromosome 
inactivation in females leads to an interspersion of functionally wild-type and 
mutant cells. This kind of mosaicism does not apply to the autosomal gene 
TBL1XR1 where mutations would affect all cells. It may also be relevant that 
TBL1 and TBLR1 exist in the same multi-protein complex, and so may 
partially complement each other’s function. These considerations may lead to 
differences between phenotypic and/or clinical consequences of MECP2 and 
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TBL mutations. An additional possibility is that TBL proteins interact with 
proteins other than MeCP2 and effects of mutations on these interactions 
could also contribute to neurological phenotypes in humans. Future work is 
needed to address these possibilities. 
The combination of structural, biochemical and functional insights presented 
here provide strong evidence that the tripartite interaction between DNA, 
MeCP2 and TBL1/TBLR1 is crucial for brain function. Our co-crystal structure 
will inform future therapeutic strategies to combat RTT and other MECP2-
related disorders. In particular, we note that small molecules that specifically 
interfere with the interaction may be useful in treating the severe neurological 
condition MECP2 Duplication syndrome. 
Materials and Methods 
Co-immunoprecipitation and pull-down assays 
Cells transiently transfected with p3xFLAG CMV 10 vectors encoding NCoR1 
and TBL1 fragments were Dounce homogenized in NE10 buffer (20 mM 
HEPES.NaOH (pH 7.5), 10 mM NaCl, 1 mM MgCl2, 0.1% Triton X-100 (v/v), 
protease inhibitors (Roche), 15 mM β-mercaptoethanol) then treated at 25 °C 
for 5 min with 250 units benzonase (Sigma) per 107 cells. The NaCl 
concentration was adjusted to 150 mM. After mixing for 20 min, lysates were 
cleared by centrifugation at 16,000 x g for 20 min. Pull-downs and co-
immunoprecipitations were performed as described previously (13). 
Antibodies used were M2 anti-FLAG (Sigma) and anti-mCherry (Chromotek). 
For Western blots antibodies used were anti-HDAC3 (Santa Cruz, sc-11417), 
anti-TBLR1 (Bethyl, A300-408A), M2 anti-FLAG (Sigma) and anti-mCherry 
(Abcam ab167453). 
 
Protein expression and purification 
TBLR1-CTD (residues 134-514) was expressed as an N-terminal 6xHis 
tagged protein in Sf9 cells infected at a density of 2 x106 cells/ml with 1:50 
virus:medium using a V2 stock. After three days, infected cells were 
resuspended in 20 mM Tris-HCl pH 7.5, 500 mM NaCl, 10 mM imidazole, 1 
mM Pefabloc (Roche) supplemented with a complete EDTA-free protease 
inhibitor cocktail tablet (Roche). Cells were sonicated on ice and the lysate 
cleared by centrifugation at 50,000 x g at 4˚C for 45 min. His-tagged protein 
was batch purified using Ni2+-NTA resin, washed twice with (20 mM Tris-HCl 
pH 7.5, 500 mM NaCl, 20 mM imidazole) and eluted with 20 mM Tris-HCl pH 
7.5, 500 mM NaCl, and 500 mM imidazole. Eluted protein was dialysed 
overnight at 4˚C into 20 mM Tris-HCl pH 7.5, 200 mM NaCl, 1 mM DTT and 
separated by size-exclusion chromatography 
Thermal Denaturation assays 
The stability of wild-type and mutant TBLR1134-514 was tested in thermal 
denaturation assays at a final protein concentration of 2 µM and 5X SYPRO 
dye. The assay was performed on Biorad IQ5 ICycler using a range of 20-
90˚C, increments of 1˚C and a hold time of 30 s. Melting temperatures were 
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obtained from the minimum of the negative first derivative of the fluorescence 
when plotted against temperature (-d(RFU)/dT vs T).  
Crystallisation and structure refinement 
The TBLR1-CTD-MeCP2 complex was formed by mixing TBLR1 (10 mg/ml) 
with a peptide corresponding to residues 285-309 of MeCP2 (MeCP2 NIDS; 
Thermo Fisher) in a protein:peptide ratio of 1:1.2. Crystals were grown by 
hanging drop vapor diffusion in 100 mM MOPS pH 7.5 and 18% PEG 3350 at 
18ºC. Crystals were cryo-protected by supplementing buffer with 30% glycerol 
and flash-cooled to 100K. Diffraction data were collected at beam line I03 at 
Diamond Light Source. Data were indexed and integrated with XDS and 
merged using SCALA (36, 37). Phases were obtained by molecular 
replacement in PHASER (38). Coordinates of hTBLR1 (PDB ID: 4LG9, (26)) 
were used as a search model. The structure was built using iterative 
rebuilding in COOT and refinement with PHENIX using NCS restraints (39, 
40).  
Surface Plasmon Resonance assays 
Wild-type and mutant biotin-PEG-PEG-MeCP2 peptides spanning residues 
285-313 (MeCP2-NID), and biotin-PEG-PEG-MeCP2 285-309 (MeCP2-NIDS) 
(Thermo Fisher) were immobilized on SA sensor chips (GE Healthcare). All 
experiments were performed at 25˚C using a BIAcore T200 (GE Healthcare).	  
Binding reactions were carried out in 20 mM Tris-HCl pH 7.5, 200 mM NaCl, 1 
mM DTT. MeCP2 peptides (20 nM) were injected onto the chip to maximum 
Response Unit (RU) values of ~10. Channels for MeCP2-NID, MeCP2-NIDS 
and MeCP2-NID R306C peptides and a reference channel were used in 
parallel. TBLR1 (or a TBLR1 mutant), supplemented with 100U/ml of heparin, 
was injected at 30 µl/min for 30 seconds at concentrations increasing from 
0.625 µM to 40 µM. Data were analysed using the BIAcore T200 Evaluation 
software. Binding constants were derived from steady-state analysis.  
Co-localisation assays 
Indicated mutations were introduced into pEGFP-C3-MeCP2 and pN1-TBL1-
mCherry expression vectors, as previously (13). NIH-3T3 cells were grown on 
glass coverslips and transfected using JetPei (Polyplus). After 24 hours, the 
growth medium was changed, and after 48 hours, cells were fixed in 4% 
paraformaldehyde for 15 min. Cells were then washed with PBS and stained 
with DAPI before being mounted on slides with Prolong Diamond (Life 
Technologies). Finally, slides were photographed using a Zeiss Airyscan 
microscope.  
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Table 1. Binding constants derived from non-linear regression analysis of 
SPR data; s.e., standard error; n.b., no binding. R2, weighted residual of fit. 
 
 MeCP2-NID  MeCP2-NIDS  
TBLR1 KD ± s.e. (µM) RU max R2  χ2 KD ± s.e. (µM) 
RU 
max R
2  χ2 
Structure-
based mutants    
 
    
Wild-type 9.5 ± 0.5 81.5 0.998 0.80 12.9 ± 0.8 105.7 0.998 1.41 
E171A ≥ 40 32.5 0.873 5.09 ≥ 40 77.5 0.995 0.82 
E171Q ≥ 40 60.3 0.989 1.20 ≥ 40 72.4 0.996 0.74 
C214S 6.6 ± 0.4 97.45 0.998 1.83 8.9 ± 0.5 134.4 0.998 2.74 
D313N n.b. - - - n.b. - - - 
E351A 32  ± 5 57.2 0.993 0.88 ≥ 40 83.0 0.998 0.28 
E351D 11.4 ± 0.5 84.3 0.999 0.53 16.3 ± 0.7 114.5 0.999 0.69 
D369A n.b. - - - n.b. - - - 
Y446F 10.1 ± 0.5 96.9 0.999 1.01 13.0 ± 0.7 128.2 0.999 1.55 
DECIPHER 
mutants         
D369E 29 ± 3.1 18.9 0.996 0.07 ≥ 40 27.6 0.985 0.29 
P444R 24 ± 2.3 46.1 0.996 0.45 31.6 ± 4 69.1 0.994 1.17 
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Figure Legends 
 
Figure	  1.	  TBL1/TBLR1	  and	  MeCP2	  interact	  with	  a	  common	  fragment	  of	  NCoR1.	  	  
(a)	  Domain	  overview	  of	  MeCP2	  (orange)	  and	  the	  NCoR/SMRT	  complex	  components,	  
TBLR1	  (blue)	  and	  NCoR1	  (brown).	  Above	  is	  a	  sequence	  of	  MeCP2	  NID	  (orange)	  with	  
residues	  mutated	  in	  RTT	  highlighted	  in	  yellow.	  Above	  the	  sequence	  are	  RTT	  
mutations	  used	  in	  this	  study.	  The	  T308	  phosphorylation	  site	  is	  marked	  with	  a	  P	  in	  a	  
red	  circle.	  A	  previously	  characterized	  interaction	  between	  TBL1	  and	  NCoR1	  is	  
indicated	  with	  gray	  dotted	  lines.	  Domains	  are	  annotated	  as:	  MBD,	  methylated	  DNA	  
binding	  domain;	  NID,	  NCoR	  interaction	  domain;	  WD40,	  domain	  containing	  8	  WD40	  
motif	  repeats;	  DAD,	  deacetylase	  activating	  domain.	  Brown	  lines	  indicate	  NCoR1	  
deletion	  mutants.	  Results	  of	  binding	  interactions	  between	  NCoR1	  fragments	  with	  
TBL1	  and	  MeCP2	  are	  summarized;	  n.d.,	  not	  determined.	  (b)	  Pull-­‐down	  of	  FLAG-­‐
NCoR1	  fragments	  from	  HeLa	  cell	  extracts	  by	  MeCP2-­‐NID	  peptide.	  (c)	  Co-­‐IP	  of	  
endogenous	  TBLR1	  with	  FLAG-­‐NCoR1	  fragments	  from	  transfected	  HeLa	  cells.	  	  
	  
Figure	  2.	  MeCP2	  binds	  directly	  to	  TBL1	  C-­‐terminal	  domain.	  	  
(a)	  Overview	  of	  TBL1/	  TBLR1	  domain	  structure	  (blue).	  Blue	  lines	  show	  deletion	  
mutants	  of	  TBL1.	  Results	  from	  pull-­‐down	  assays	  are	  summarized	  beside	  the	  overview	  
of	  deletion	  mutants.	  (b)	  Pull-­‐down	  assay	  of	  full-­‐length	  and	  deletion	  fragments	  of	  
TBL1	  from	  HeLa	  cell	  extracts	  with	  MeCP2	  NID	  peptide.	  B	  indicates	  samples	  bound	  to	  
beads	  containing	  biotinylated	  peptide.	  Peptides	  were	  run	  as	  a	  control	  in	  adjacent	  
lanes	  (P).	  (c)	  Pull-­‐down	  assay	  of	  purified	  TBLR1-­‐CTD	  with	  wild-­‐type	  MeCP2	  NID	  
peptide	  and	  peptides	  encoding	  RTT	  mutations	  or	  phosphoThr308	  modification.	  (d)	  
Binding	  interaction	  between	  MeCP2	  peptides	  and	  TBLR1-­‐CTD	  by	  surface	  plasmon	  
resonance.	  Steady	  state	  binding	  curves	  were	  derived	  from	  binding	  reactions	  with	  
MeCP2	  NID	  (blue),	  MeCP2	  NIDS	  (gray)	  and	  MeCP2	  NID	  R306C	  mutant	  (red)	  peptides.	  	  
	  
Figure	  3.	  TBL1	  chimeras	  allow	  identification	  of	  MeCP2	  binding	  residues.	  	  
(a)	  Overview	  of	  mouse-­‐sponge	  chimeras.	  Wild-­‐type	  and	  mutant	  MeCP2-­‐NID	  peptides	  
were	  used	  to	  pull-­‐down	  FLAG-­‐tagged	  TBL1	  chimeras.	  Binding	  interactions	  with	  
MeCP2	  are	  summarized	  next	  to	  the	  schema.	  (b)	  Pull-­‐down	  assays	  of	  wild-­‐type	  and	  
mutant	  MeCP2	  NID	  with	  FLAG-­‐tagged	  mouse	  TBL1	  mutants	  with	  individual	  amino	  
acids	  converted	  to	  residues	  found	  in	  sponge.	  	  
 
Figure	  4.	  Co-­‐crystal	  structure	  of	  the	  TBLR1-­‐MeCP2	  complex.	  	  
	  (a)	  Cartoon	  representation	  of	  TBLR1-­‐CTD	  (blue)	  with	  MeCP2	  NID	  (orange)	  shown	  as	  
ribbon.	  WD40	  blades	   are	   coloured	   shades	  of	   blue,	  with	   a	   gradient	  of	   dark	   to	   light	  
from	  N-­‐	   to	   C-­‐terminus.	   (b)	   Surface	   representation	   of	   TBLR1-­‐CTD	  with	  MeCP2	  NID.	  
The	   view	   is	   rotated	   90°	   around	   the	   horizontal	   axis	   compared	   to	   (a)	   and	   WD40	  
repeats	   1-­‐3	   are	   removed	   for	   clarity.	   (c)	   Surface	   representation	   of	   TBLR1	   with	   the	  
view	  as	   in	   (a).	  Yellow	   indicates	   the	  area	  buried	  by	  MeCP2.	   (d)	  Electrostatic	   surface	  
representation	  of	  TBLR1-­‐CTD	  (APBS)	  colored	  red	  to	  blue	  from	  -­‐5.5	  to	  +5.5	  kT/e.	  (e)	  
Surface	   conservation	  analysis	  of	   TBLR1	   (CONSURF),	   colored	   from	  blue	   (variable)	   to	  
purple	  (conserved).	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Figure	  5.	  RTT	  mutations	  disrupt	  key	  interactions	  between	  MeCP2	  and	  TBLR1.	  	  
(a)	  Close-­‐up	  of	  MeCP2	  NID	  (orange)	  bound	  to	  TBLR1	  (blue).	  Only	  residue	  side	  chains	  
that	  make	  contacts	  with	  MeCP2	  are	  shown.	  Hydrogen	  bonds	  are	  grey	  dotted	   lines.	  
(b)	  The	  same	  view,	  rotated	  180°	  around	  the	  vertical	  axis.	  (c-­‐f)	  MeCP2	  is	  shown	  with	  
RTT	  mutations	  modeled	  and	  wild-­‐type	  side	  chains	  shown	  as	  transparent	  ghosts:	   (c)	  
R306C	   (d)	   K304E,	   (e)	   P302R	   and	   (f)	   K305R.	   Orange	   arrows	   indicate	   the	   mutated	  
residue.	  
	  
Figure	  6.	  TBL1/TBLR1	  surface	  mutations	  do	  not	  bind	  MeCP2.	  	  
(a)	  Map	  of	  mutations	  in	  TBLR1	  and	  TBL1.	  (b)	  Steady	  state	  SPR	  binding	  curves	  of	  wild-­‐
type	  (blue)	  and	  mutant	  (gray	  and	  black)	  TBLR1	  proteins	  interacting	  with	  immobilized	  
MeCP2	  NID	  peptide.	  Wild-­‐type	  TBLR1	  with	  R306C	  NID	  peptide	  (red)	  is	  a	  negative	  
control.	  (c)	  Recruitment	  of	  TBL1-­‐mCherry	  to	  heterochromatin	  foci	  in	  NIH-­‐3T3	  cells	  by	  
EGFP-­‐MeCP2.	  DAPI	  staining	  (blue),	  green	  and	  red	  fluorescence	  and	  a	  merged	  image	  
are	  shown	  for	  wild-­‐type	  and	  mutant	  proteins.	  	  The	  scale	  bar	  represents	  5	  micron.	  
Wild-­‐type	  cells	  show	  colocalistion	  in	  63%	  of	  cells	  (n=27).	  Mutants	  E184A,	  E364A,	  
E382A	  and	  D326N	  show	  colocalisation	  in	  0-­‐1	  cells	  in	  14.	  Y459F	  shows	  colocalisation	  
in	  55%	  of	  cells	  (n=27).	  	  	  
 
Figure	  7.	  Missense	  mutations	  associated	  with	  developmental	  delay	  block	  MeCP2	  
binding	  to	  TBL1/TBLR1.	  	  
(a)	  Map	  of	  mutations	  in	  TBLR1	  and	  TBL1.	  	  (b)	  Pull-­‐down	  assays	  of	  equivalent	  
mutations	  in	  TBL1	  with	  MeCP2	  NID	  peptide	  or	  a	  mutant	  peptide	  containing	  the	  
K305R	  RTT	  mutation.	  (c)	  Recruitment	  of	  TBL1-­‐mCherry	  (red)	  and	  developmental	  
delay	  mutants	  by	  EGFP-­‐MeCP2	  (green)	  to	  heterochromatin	  foci	  (blue)	  in	  NIH-­‐3T3	  
cells.	  The	  scale	  bar	  represents	  5	  micron.	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Supplemental Information 
 
Supplementary Methods 
Fluorescence anisotropy assays  
 
All assays were carried out in a final volume of 100 µl in black opaque 96-well 
plates (Greiner Bio One) using a SpectraMax M5 multimode plate reader at 
room temperature. Fluorescein-labeled MeCP2 298-309 peptide, at a final 
concentration of 100 nM, was titrated against protein concentrations ranging 
from 50 nM to 40 µM. Data were analyzed using non-linear regression with 
eq. 1 where Rf and Rb are the anisotropies of the free and bound receptor, 
respectively, LT is the total ligand concentration, and KD is the dissociation 
constant.  𝒀 = 𝑹𝒇 + 𝑹𝒃 − 𝑹𝒇 ∗ 𝑳𝑻!𝑲𝑫!𝑿!   !𝑳𝑻!𝑲𝑫!𝑿 𝟐!𝟒∗𝑲𝑫∗𝑿𝟐∗𝑳𝑻 	  	  	  	  	  	  (1)	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Table S1.  Data collection and refinement statistics 
 TBLR1-CTD-MeCP2-NIDS  
Data Collection  
Beamline DLS I03 
Wavelength (Å) 0.976250 
Resolution range Å (high resolution shell)* 49.6  - 2.5 (2.6  - 2.5) 
Space group P 1 
Unit cell a,b,c (Å) 
              α, β, γ (°) 
42.6  58.6  155.1  
97.6  91.2  90.2 
Total reflections 120672 (10968) 
Unique reflections 50648 (4583) 
Multiplicity 2.4 (2.4) 
Completeness (%) 98 (88) 
Mean I/σ(I) 9.9 (2.3) 
Wilson B-factor (Å2) 33.5 
R-merge 0.08 (0.4) 
CC1/2 0.97 (0.69) 
  
Refinement  
Reflections used in refinement 50632 (4583) 
Rwork 0.20  
Rfree 0.25  
Number of non-hydrogen atoms 10400 
  protein 9619 
  peptide 153 
  solvent 619 
r.m.s. (bonds) 0.004 
r.m.s (angles) 0.72 
Ramachandran favored (%) 95.3 
Ramachandran allowed (%) 4.3 
Ramachandran outliers (%) 0.4 
Clashscore 7.1 
Average B-factor (Å2) 50.2 
  protein 52.6 
  peptide 46.1 
  solvent 52.3 
*Statistics for the highest-resolution shell are shown in parentheses. 
  
	   28	  
 
 
 
Supplemental Figures 
 
Figure S1  
(a) Sequence alignment for MeCP2 NID domain. Residues that interact with TBLR1 are marked with 
blue dots. T308, which can be phosphorylated is marked with a yellow dot. Known RTT missense 
mutations used in this study are marked below. (b) Sequence alignment of TBL1 and TBLR1 from 
vertebrates and sponge. Secondary structure elements are shown above the sequence. Residues 
interacting with MeCP2 are marked with orange dots. Residues mutated in this study are marked with 
red triangles.  
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Figure S2  
(a) Coomassie stained gel of purified TBLR1-CTD. (b) Raw surface plasmon resonance traces for 
wild-type TBLR1-CTD with MeCP2 mutant and wild-type peptides. The key indicates the 
concentrations of TBLR1 used in a dilution series. Binding curves in Fig. 2 were calculated from 
equilibrium measurements from these data. (c) Fluorescence anisotropy binding with minimal 11mer 
peptide of MeCP2 (residues 298-309). Anisotropy is measured in arbitrary units (A.U.). The binding 
constant was derived from fitting three independent experiments and is expressed as the mean KD ± 
standard error (s.e.). 
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Figure S3  
(a) Pull-down assay of biotinylated-MeCP2-NID wild-type or mutant peptide with TBL1 from sponge 
and Drosophila. (b) Sequence alignment of TBL1 from mouse and sponge, as well as TBL1-chimera2, 
indicating segments of the sequence that were used for mutagenesis analysis. (c) Pull-down assays 
between MeCP2 NID and local TBL1 mouse-> sponge mutants from HeLa cell extracts. (d) Co-IP of 
HDAC3 with wild-type and mutant TBL1. (e)	  Location of residue equivalent to E364 on the human 
TBLR1 structure (PDBid 4LG9). 
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Figure S4  
(a) Divergent stereo view of the MeCP2 NID peptide (yellow) bound to TBLR1 (blue) with Fo-Fc omit 
map calculated from coordinates where the MeCP2 peptide was omitted. This map is contoured at 
2.5σ. (b) A comparison of peptide recognition in two histone H3 binding WD40 domains, WDR5 
(PDBid 4A7J) and EED (PDBid 3K26) that feature recognition of a basic motif. The orientation of the 
viewpoint is rotated 90° around the y-axis with respect to (a). Each WD40 domain was superposed 
using the SSM function in COOT and are aligned primarily on the first 4 repeats. Root mean square 
deviations of fit are 2.6 Å and 2.7 Å respectively. WD40 repeats 4 and 5 have been removed for clarity. 
Methylated arginine and lysine residues from histone H3 are recognized by aromatic cages, in contrast 
to the ionic interactions observed with basic residues in MeCP2.  
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Figure S5 
(a) Raw surface plasmon resonance traces for TBLR1-CTD mutants with MeCP2 NID peptide. (b) 
Alterations in melting temperature (Tm) of TBLR1 mutants using a thermal denaturation assay. 
Change in Tm is compared to wild-type. (c) co-IP of mCherry TBLR1 or mCherry importin α4 
(KPNA4) with NCoR/SMRT components. Samples tested were: KPNA4 (negative control, has a 
similar molecular mass as TBLR1), wild-type TBLR1 (positive control) and TBLR1 point mutants. 
Co-purification of NCoR/SMRT was determined by probing with α-HDAC3; in = input; IP = 
immunoprecipitate.  
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Figure S6 
(a) Overview of TBLR1 mutations associated with developmental delay without (dark green) or with 
(light green) autism. Models of P444R and D369E mutations (pink) are shown in inset boxes. (b) Co-
IP of mCherry TBLR1 or mCherry importin α4 (KPNA4) with NCoR/SMRT components. Samples 
tested were: KPNA4 (negative control), wild-type TBL1 (positive control) and TBL1 point mutants. 
Residues in TBLR1 that are equivalent to these mutations are D369E, P444R and E171A. Co-
purification of NCoR/SMRT was determined by probing with α-HDAC3; in = input; IP = 
immunoprecipitate. (c) Thermal denaturation assays for developmental delay mutants showing change 
in Tm with respect to wild-type. (d) SPR binding curves for NID and NIDS peptides with 
developmental delay mutants. Curves for wild-type TBLR1 protein are shown with wild-type (blue) 
and RTT mutant peptides (red). Mutant TBLR1 proteins with wild-type peptide are shown in gray and 
black. 	  
	  
